imipenem


Also found in: Dictionary, Thesaurus, Wikipedia.
Related to imipenem: Meropenem, vancomycin

imipenem

 [im″ĭ-pen´em]
a β-lactam antibiotic with a broad spectrum of activity against gram-positive and gram-negative organisms. Because it is metabolized in the kidneys, it is administered with the enzyme inhibitor cilastatin in order to decrease the amount of it that is degraded by an enzyme in the kidneys.
Miller-Keane Encyclopedia and Dictionary of Medicine, Nursing, and Allied Health, Seventh Edition. © 2003 by Saunders, an imprint of Elsevier, Inc. All rights reserved.

im·i·pen·em

(im'i-pen'em),
A beta-lactam antibiotic derived from thienamycin with broad spectrum activity used, in combination with cilastin, to treat various infections. Classified as a carbapenem antibiotic.
Farlex Partner Medical Dictionary © Farlex 2012

im·i·pen·em

(im'i-pen'em)
A beta-lactam antibiotic derived from thienamycin with broad spectrum activity used, in combination with cilastin, to treat various infections.
Medical Dictionary for the Health Professions and Nursing © Farlex 2012

imipenem

An ANTIBIOTIC enzyme inhibitor resistant to breakdown by most beta-lactamases. It is active against a wide range of bacteria. The drug is on the WHO official list. A brand name with cilastatin is Primaxin.
Collins Dictionary of Medicine © Robert M. Youngson 2004, 2005

im·i·pen·em

(im'i-pen'em)
A β-lactam antibiotic with broad spectrum activity used to treat various infections.
Medical Dictionary for the Dental Professions © Farlex 2012
References in periodicals archive ?
Among 152, 103 (68%) isolates were resistant to Meropenem and 95 (63%) isolates were resistant to imipenem. It was observed that Klebsiella pneumoniae 39 (26%), Pseudomonas aeruginosa 29 (19%) and Escherichia coli 21 (14%) were predominant carbapenem-resistant isolates followed by Serratia marcescens 3 (3%), Klebsiella oxytoca 2 (1%) and Enterobacter agglomerans 2 (1%) as shown in Figure 2.
Also, the minimum inhibitory concentration (MIC) value of imipenem for clinical isolates of K.
All carbapenemase positive strains, including MBL and CHDL were found to be resistant or intermediately susceptible to carbapenems with MICs of imipenem and meropenem ranging from 8 to >128 mg/L.
In the present study imipenem, cefixime and amikacin used to prevent the swarming of P.
coli isolates showed more sensitivity to Amikacin 57(76%) followed by Imipenem 57(66.67%), Ofloxacin 48(64%), Ciprofloxacin 44(58.67%), Norfloxacin 42(56%) and 75(100%) were resistant to Penicillin, Ceftriaxone, Ceftazidime and Cefotaxime (Table-2 and Figure-2).
Staphylococcus aureus isolates showed least resistance to imipenem (2.6%) followed by linezolid.
Antibiotic susceptibility testing was determined for this isolates to routinely used antibiotics such as to piperacillintazobactam, cefotaxime, ceftazidime, tetracycline, cotrimoxazole, aztreonam, gentamicin, and imipenem by Kirby Bauer disc diffusion method as per CLSI guideline.
Resistance by disk diffusion technique noted in Salmonella Paratyphi A was ampicillin 60%, chloramphenicol 40%, cotrimoxazole 38%, ceftriaxone 7.9%, ciprofloxacin 8%, cefpodoxime 7.9%, imipenem and ertapenem 2.6%, aztreonam 1.3%, moxifloxacin 6.6%, and gatifloxacin 1.3%.
This situation is alarming as not only the prevalence of the non-fermenter, Acinetobacter species increasing so is the imipenem resistance which has increased from 60.6% to 74% within two years.
Few Genetic Mutations Observed in Two Clonally Related Carbapenem-Heteroresistant Strains after Lethal Imipenem Exposure.